Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
Would you consider nivolumab/relatlimab as a salvage therapy option for advanced melanoma patients who progressed on single-agent PD-1 inhibitor?
Related Questions
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?
How do you decide between treating with neoadjuvant nivolumab/ipilimumab versus neoadjuvant pembrolizumab for patients with resectable, clinical node + Stage III melanoma given the NADINA trial results?
How would you treat locally advanced melanoma of the scalp with several in transit lesions and a metastatic lesion to the parotid if the patient is progressing on immunotherapy such as pembrolizumab?
Would you consider adjuvant immunotherapy for a patient with high-risk (N3 nodes) Merkel cell carcinoma following definitive surgical resection and adjuvant radiation therapy?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What is the role of adrenalectomy in managing isolated recurrence of stage IIIc melanoma, occurring 2 years after the original diagnosis, in a patient who declined adjuvant therapy?
How do you approach the management of patients with locally advanced unresectable mucosal melanoma in the head and neck region?
How would you manage a cardiac metastasis from Merkel cell carcinoma?
